Aim — to study the influence of immunomodulating medicine Galavit on cellular immune status in patients with essential hypertension. Material and methods. There were 104 patients (54 women and 50 men) aged 55—75 years with essential hypertension degree 3, stage II, risk 4, uncomplicated hypertensive crisis. Random numbers were used to select 52 patients (main group), other 52 patients were included into control group. Both groups were similar by sex, age, duration of disease and blood pressure (BP) at admission. Mean age of patients in the main group was 61.8±1.6 years, duration of disease — 12.4±1.3 years, systolic blood pressure — 204±3.4 mm Hg. Conventional hypotensive therapy was combined with Galavit suppository 100 mg daily per rectum during 10 days in the main group. Hypotensive therapy alone was applied in the control group. Flow cytophotometry was used in all patients to determine T-lymphocytes and their subpopulations (T-helpers and T-suppressors), B-lymphocytes and natural killers in venous blood. Results. Signs of crisis N.A. Ratner type I (excitation, fright, tachycardia, facial hyperemia, headache and nausea) were noted in 50 people. Symptoms of crisis type II (pallor, lethargy, chest pain, black spots in eyes, headache, nausea and vomiting) were observed in other 54 patients. Galavit intake was followed by significant improvement of general health and 1.3 times faster achievement of target blood pressure. Galavit administration led to reliable changes in the content of T-lymphocytes, T-supressors, T-helpers, B-lymphocytes and natural killers in patients with hypertension both during hypertensive crisis and 1-year follow-up. Conclusion. The use of Galavit is perspective since the medicine improves overall health of patients and stabilizes blood pressure. These features result 1.5 times reduced hospital-stay.